SCHEMBL3012045

SCHEMBL3012045

O=S(=O)(c1ccc(Cl)cc1)C1CCN(c2nc(-c3ccccc3)cs2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.58
NPC1 O15118 5/20 0.58
MAPT P10636 5/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
MAPK1 P28482 4/20 0.55
LMNA P02545 3/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
SMN1; SMN2 Q16637 7/20 0.53
AR P10275 3/20 0.53
TP53 P04637 2/20 0.53
ALOX15 P16050 1/20 0.53
HSD17B10 Q99714 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
FFAR2 O15552 1/20 0.50
HTT P42858 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KDM1A O60341 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006940 0.94 SMN1; SMN2 (0.58) RAB9ANPC1MAPTCYP1A2CYP2C9
SCHEMBL3006846 0.91 MAPK1 (0.55) RAB9ANPC1MAPTCYP1A2CYP2C9
SCHEMBL3013329 0.90 SMN1; SMN2 (0.51) RAB9ANPC1MAPTCYP1A2CYP2C9
SCHEMBL3003995 0.89 SMN1; SMN2 (0.57) RAB9ANPC1MAPTCYP1A2CYP2C9
SCHEMBL3001102 0.89 SMN1; SMN2 (0.57) RAB9ANPC1MAPTCYP1A2CYP2C9
SCHEMBL3014611 0.89 SMN1; SMN2 (0.57) RAB9ANPC1MAPTCYP1A2CYP2C9
SCHEMBL3001913 0.89 SMN1; SMN2 (0.61) RAB9ANPC1MAPTCYP1A2CYP2C9
SCHEMBL3009419 0.89 SMN1; SMN2 (0.60) RAB9ANPC1MAPTCYP1A2CYP2C9
SCHEMBL3011753 0.89 KMT2A (0.58) RAB9ANPC1MAPTCYP1A2CYP2C9
SCHEMBL3012849 0.89 SMN1; SMN2 (0.58) RAB9ANPC1MAPTCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885NPC1 15/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.